Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts

Beverly A. Teicher, Edward A. Bump, Sanjeewani Palayoor, David Northey, C. Norman Coleman

Research output: Contribution to journalArticle

Abstract

Radiation therapy is very useful in the treatment of prostate cancer; however, local treatment failure still occurs in the majority of patients with locally advanced disease. The growth and progression of tumors involve signaling through protein growth factors and small molecules such as arachidonic acid cascade products. In order to develop novel agents to enhance the efficacy of radiation therapy for patients with prostate cancer, the ability of signal transduction inhibitors including (1) the antiandrogen, flutamide; (2) the anti-inflammatory agent, ibuprofen; (3) the growth factor receptor antagonist, suramin; (4) the retinoid, all-trans-retinoic acid; and (5) the calcium pump inhibitor, thapsigargin to enhance the response of the human prostate carcinoma xenografts DU-145 and LN-CaP, was assessed. Flutamide acted as a radiation protector of the androgen independent DU-145 tumor but produced an additive antitumor effect in combination with fractionated radiation therapy in the androgen dependent LNCaP tumor. Administration of suramin or thapsigargin along with radiation therapy provided little or no tumor growth delay compared with radiation therapy alone. Treatment with all-trans-retinoic acid did not alter the response of the DU-145 to radiation therapy but increased the response of LNCaP tumor to radiation therapy. Administration of ibuprofen along with radiation therapy was most effective. The radiation dose modifying factor for ibuprofen in the DU-145 tumor was 1.8 and 1.7 for a 1-week and a 2-week fractionated regimen, respectively. Administration of ibuprofen along with radiation therapy to animals bearing the LNCaP tumor resulted in a 2-fold increase in tumor growth delay compared with radiation therapy alone. Further investigation of inhibitors of the arachidonic acid cascade as radiation modifiers is warranted.

Original languageEnglish (US)
Pages (from-to)221-230
Number of pages10
JournalRadiation Oncology Investigations
Volume4
Issue number5
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Heterografts
inhibitors
Prostate
radiation therapy
Signal Transduction
Radiotherapy
cancer
Carcinoma
tumors
Ibuprofen
Neoplasms
Flutamide
Suramin
acids
Thapsigargin
Radiation
Tretinoin
Arachidonic Acid
Androgens
Prostatic Neoplasms

Keywords

  • flutamide
  • ibuprofen
  • prostate carcinoma xenografts
  • radiation sensitization
  • retinoic acid
  • suramin
  • thapsigargin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Radiological and Ultrasound Technology

Cite this

Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts. / Teicher, Beverly A.; Bump, Edward A.; Palayoor, Sanjeewani; Northey, David; Coleman, C. Norman.

In: Radiation Oncology Investigations, Vol. 4, No. 5, 1996, p. 221-230.

Research output: Contribution to journalArticle

Teicher, Beverly A. ; Bump, Edward A. ; Palayoor, Sanjeewani ; Northey, David ; Coleman, C. Norman. / Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts. In: Radiation Oncology Investigations. 1996 ; Vol. 4, No. 5. pp. 221-230.
@article{158f65e3874c45d09681755ae2cda40e,
title = "Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts",
abstract = "Radiation therapy is very useful in the treatment of prostate cancer; however, local treatment failure still occurs in the majority of patients with locally advanced disease. The growth and progression of tumors involve signaling through protein growth factors and small molecules such as arachidonic acid cascade products. In order to develop novel agents to enhance the efficacy of radiation therapy for patients with prostate cancer, the ability of signal transduction inhibitors including (1) the antiandrogen, flutamide; (2) the anti-inflammatory agent, ibuprofen; (3) the growth factor receptor antagonist, suramin; (4) the retinoid, all-trans-retinoic acid; and (5) the calcium pump inhibitor, thapsigargin to enhance the response of the human prostate carcinoma xenografts DU-145 and LN-CaP, was assessed. Flutamide acted as a radiation protector of the androgen independent DU-145 tumor but produced an additive antitumor effect in combination with fractionated radiation therapy in the androgen dependent LNCaP tumor. Administration of suramin or thapsigargin along with radiation therapy provided little or no tumor growth delay compared with radiation therapy alone. Treatment with all-trans-retinoic acid did not alter the response of the DU-145 to radiation therapy but increased the response of LNCaP tumor to radiation therapy. Administration of ibuprofen along with radiation therapy was most effective. The radiation dose modifying factor for ibuprofen in the DU-145 tumor was 1.8 and 1.7 for a 1-week and a 2-week fractionated regimen, respectively. Administration of ibuprofen along with radiation therapy to animals bearing the LNCaP tumor resulted in a 2-fold increase in tumor growth delay compared with radiation therapy alone. Further investigation of inhibitors of the arachidonic acid cascade as radiation modifiers is warranted.",
keywords = "flutamide, ibuprofen, prostate carcinoma xenografts, radiation sensitization, retinoic acid, suramin, thapsigargin",
author = "Teicher, {Beverly A.} and Bump, {Edward A.} and Sanjeewani Palayoor and David Northey and Coleman, {C. Norman}",
year = "1996",
doi = "10.1002/(SICI)1520-6823(1996)4:5<221::AID-ROI4>3.0.CO;2-#",
language = "English (US)",
volume = "4",
pages = "221--230",
journal = "Radiation Oncology Investigations",
issn = "1065-7541",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts

AU - Teicher, Beverly A.

AU - Bump, Edward A.

AU - Palayoor, Sanjeewani

AU - Northey, David

AU - Coleman, C. Norman

PY - 1996

Y1 - 1996

N2 - Radiation therapy is very useful in the treatment of prostate cancer; however, local treatment failure still occurs in the majority of patients with locally advanced disease. The growth and progression of tumors involve signaling through protein growth factors and small molecules such as arachidonic acid cascade products. In order to develop novel agents to enhance the efficacy of radiation therapy for patients with prostate cancer, the ability of signal transduction inhibitors including (1) the antiandrogen, flutamide; (2) the anti-inflammatory agent, ibuprofen; (3) the growth factor receptor antagonist, suramin; (4) the retinoid, all-trans-retinoic acid; and (5) the calcium pump inhibitor, thapsigargin to enhance the response of the human prostate carcinoma xenografts DU-145 and LN-CaP, was assessed. Flutamide acted as a radiation protector of the androgen independent DU-145 tumor but produced an additive antitumor effect in combination with fractionated radiation therapy in the androgen dependent LNCaP tumor. Administration of suramin or thapsigargin along with radiation therapy provided little or no tumor growth delay compared with radiation therapy alone. Treatment with all-trans-retinoic acid did not alter the response of the DU-145 to radiation therapy but increased the response of LNCaP tumor to radiation therapy. Administration of ibuprofen along with radiation therapy was most effective. The radiation dose modifying factor for ibuprofen in the DU-145 tumor was 1.8 and 1.7 for a 1-week and a 2-week fractionated regimen, respectively. Administration of ibuprofen along with radiation therapy to animals bearing the LNCaP tumor resulted in a 2-fold increase in tumor growth delay compared with radiation therapy alone. Further investigation of inhibitors of the arachidonic acid cascade as radiation modifiers is warranted.

AB - Radiation therapy is very useful in the treatment of prostate cancer; however, local treatment failure still occurs in the majority of patients with locally advanced disease. The growth and progression of tumors involve signaling through protein growth factors and small molecules such as arachidonic acid cascade products. In order to develop novel agents to enhance the efficacy of radiation therapy for patients with prostate cancer, the ability of signal transduction inhibitors including (1) the antiandrogen, flutamide; (2) the anti-inflammatory agent, ibuprofen; (3) the growth factor receptor antagonist, suramin; (4) the retinoid, all-trans-retinoic acid; and (5) the calcium pump inhibitor, thapsigargin to enhance the response of the human prostate carcinoma xenografts DU-145 and LN-CaP, was assessed. Flutamide acted as a radiation protector of the androgen independent DU-145 tumor but produced an additive antitumor effect in combination with fractionated radiation therapy in the androgen dependent LNCaP tumor. Administration of suramin or thapsigargin along with radiation therapy provided little or no tumor growth delay compared with radiation therapy alone. Treatment with all-trans-retinoic acid did not alter the response of the DU-145 to radiation therapy but increased the response of LNCaP tumor to radiation therapy. Administration of ibuprofen along with radiation therapy was most effective. The radiation dose modifying factor for ibuprofen in the DU-145 tumor was 1.8 and 1.7 for a 1-week and a 2-week fractionated regimen, respectively. Administration of ibuprofen along with radiation therapy to animals bearing the LNCaP tumor resulted in a 2-fold increase in tumor growth delay compared with radiation therapy alone. Further investigation of inhibitors of the arachidonic acid cascade as radiation modifiers is warranted.

KW - flutamide

KW - ibuprofen

KW - prostate carcinoma xenografts

KW - radiation sensitization

KW - retinoic acid

KW - suramin

KW - thapsigargin

UR - http://www.scopus.com/inward/record.url?scp=0030515239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030515239&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1520-6823(1996)4:5<221::AID-ROI4>3.0.CO;2-#

DO - 10.1002/(SICI)1520-6823(1996)4:5<221::AID-ROI4>3.0.CO;2-#

M3 - Article

AN - SCOPUS:0030515239

VL - 4

SP - 221

EP - 230

JO - Radiation Oncology Investigations

JF - Radiation Oncology Investigations

SN - 1065-7541

IS - 5

ER -